Patents Represented by Attorney, Agent or Law Firm Ginger Dreger
  • TRAF inhibitors
    Patent number: 6294348
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: September 25, 2001
    Assignees: Genentech Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • TRAF Inhibitors
    Patent number: 6063585
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: May 16, 2000
    Assignees: Genetech, Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • TRAF inhibitors
    Patent number: 6060303
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: May 9, 2000
    Assignees: Genetech, Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • TRAF inhibitors
    Patent number: 6004553
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: December 21, 1999
    Assignees: Genentech, Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • Methods and materials for expression of human plasminogen variant
    Patent number: 5190756
    Abstract: A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in its two-chain cleavage site. The plasminogen molecule may be purified, acylated, complexed with acylated or non-acylated fibrinolytic enzymes, and formulated into pharmaceutical compositions for use in thrombolytic therapy.
    Type: Grant
    Filed: August 29, 1991
    Date of Patent: March 2, 1993
    Assignee: Genentech, Inc.
    Inventors: Francis J. Castellino, Deborah L. Higgins